Acquiring Company
Pfizer
Acquired Company
Seagen
New YorkBothellBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmapharmaceuticalsBiotechnologyHealth CareTherapeuticsDescription
Pfizer has successfully closed the acquisition of Seagen for $43 billion, effectively removing Seagen's stock from independent trading. This merger integrates Seagen into Pfizer's oncology portfolio, shifting the focus from standalone earnings to strategic synergies and integration milestones. Investors now observe the finalized valuation and implications of the deal for future oncology advancements.
Who to call at Pfizer, and when
When Pfizer changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Pfizer raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Pfizer, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Pfizer. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Pfizer makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Seagen?
Seagen was acquired by Pfizer, based in New York. The deal was reported on January 4, 2026. Seagen is a biotechnology company focused on developing innovative therapies for cancer treatment. The company specializes in antibody-drug conjugates and has a portfolio of targeted therapies. Pfizer is publicly traded (PFE) and operates in Biotechnology.
When did Pfizer acquire Seagen?
Pfizer's acquisition of Seagen was reported on January 4, 2026. Pfizer has successfully closed the acquisition of Seagen for $43 billion, effectively removing Seagen's stock from independent trading. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Seagen do?
Seagen is a biotechnology company focused on developing innovative therapies for cancer treatment. The company specializes in antibody-drug conjugates and has a portfolio of targeted therapies. It is privately held, operating in Biotechnology, and is based in Bothell.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.